Clinical Trial: COVID-19 Reactogenicity

U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07051031) titled 'COVID-19 Reactogenicity' on July 01.

Brief Summary: The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mRNA Pfizer vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.

Study Start Date: Oct. 01, 2025

Study Type: INTERVENTIONAL

Condition: Compare Post Vaccination Reactions

Intervention: DRUG: Nuvaxovid (NVX-CoV2705)

COVID-19 vaccination

DRUG: Pfizer-BioNTech COVID-19 vaccine

COVID-19 vaccination

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Marcel Curlin

Information provided by (...